|
ASPR
BARDA | Project BioShield SRF, No-Year | Anthrax | Therapeutics | $8.8 | $0.0 | $0.0 | $0.0 | $0.0 | $8.8 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Anthrax | Vaccine | $113.9 | $254.1 | $170.0 | $250.0 | $250.0 | $1,038.0 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Biodiagnostic | | $0.0 | $0.0 | $0.0 | $0.0 | $40.0 | $40.0 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Botulinum | Botulinum
Antitoxin | $11.3 | $50.0 | $0.0 | $0.0 | $0.0 | $61.3 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Broad Spectrum Antimicrobials | | $0.0 | $60.0 | $100.0 | $140.0 | $150.0 | $450.0 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Chemical | Chemical
Countermeasures | $0.6 | $0.0 | $40.0 | $200.0 | $200.0 | $440.6 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Filoviruses | Ebola | $254.6 | $194.0 | $200.0 | $250.0 | $270.0 | $1,168.6 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Rad/Nuc | ARS - Skin/
Lung/GI | $154.9 | $80.0 | $80.0 | $100.0 | $100.0 | $514.9 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Rad/Nuc | Biodosimetry | $1.8 | $3.2 | $45.0 | $25.0 | $25.0 | $100.0 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Rad/Nuc | Thermal Burns | $25.2 | $20.7 | $30.0 | $75.0 | $75.0 | $225.9 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Smallpox | Antivirals | $101.9 | $25.0 | $20.0 | $0.0 | $0.0 | $146.9 |
|---|
ASPR
BARDA | Project BioShield SRF, No-Year | Smallpox | Vaccine | $37.0 | $48.0 | $50.0 | $0.0 | $0.0 | $135.0 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual Appropriations | Pandemic
Influenza | International
MCM
and Sample
Testing Initiative | $0.0 | $0.0 | $0.0 | $10.0 | $10.0 | $20.0 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual Appropriations | Pandemic
Influenza | Vaccine
Stockpile,
Storage, Stability,
and Testing | $2.1 | $28.0 | $28.0 | $117.0 | $117.0 | $292.1 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual Appropriations | Pandemic
Influenza | Vx AD
(Universal,
Cell and Recomb) | $25.9 | $0.0 | $0.0 | $0.0 | $0.0 | $25.9 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual No-Year | Pandemic
Influenza | Ventilators/
Respirators/
Diagnostics AD | $0.0 | $20.0 | $20.0 | $220.7 | $220.7 | $481.4 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual No-Year | Pandemic
Influenza | Facilities, Infrastructure Readiness, and Sustainability | $12.0 | $130.0 | $90.0 | $264.2 | $172.2 | $668.4 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual No-Year | Pandemic
Influenza | Fill/Finish Network | $2.7 | $0.0 | $0.0 | $0.0 | $0.0 | $2.7 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual No-Year | Pandemic
Influenza | Infrastructure | $83.2 | $0.0 | $0.0 | $0.0 | $0.0 | $83.2 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual No-Year | Pandemic
Influenza | Therapeutics Advanced Development | $49.3 | $42.0 | $55.0 | $233.9 | $203.8 | $584.0 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual No-Year | Pandemic
Influenza | Vx AD
(Improved vaccines incl. cell and recombinant technologies) | $48.7 | $33.0 | $60.0 | $661.4 | $525.1 | $1,328.2 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual No-Year | Pandemic
Influenza | Vaccine Stockpile, Storage, Stability, and Testing | $9.1 | $0.0 | $0.0 | $29.3 | $12.0 | $50.4 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Annual No-Year | Pandemic
Influenza | MCM
Innovation | $10.0 | $0.0 | $0.0 | $5.0 | $5.0 | $20.0 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Sup Bal No-Year | Pandemic
Influenza | Diagnostics AD | $24.0 | $0.0 | $0.0 | $0.0 | $0.0 | $24.0 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Sup Bal No-Year | Pandemic
Influenza | Vx AD (Improved vaccines including cell and recombinant technologies) | $0.0 | $9.6 | $0.0 | $0.0 | $0.0 | $9.6 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Sup Bal No-Year | Pandemic
Influenza | Vaccine Stockpile, Storage, Stability,
and Testing | $0.0 | $38.0 | $0.0 | $0.0 | $0.0 | $38.0 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Sup Bal No-Year | Pandemic
Influenza | Therapeutics Advanced Development | $0.0 | $56.0 | $0.0 | $0.0 | $0.0 | $56.0 |
|---|
ASPR
BARDA | Pandemic Influenza - PHSSEF, Sup Bal No-Year | Pandemic
Influenza | Facilities, Infrastructure Readiness, and Sustainability | $0.0 | $0.0 | $148.4 | $0.0 | $0.0 | $148.4 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Anthrax | Therapeutics | $1.2 | $4.0 | $0.0 | $0.0 | $0.0 | $5.2 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Anthrax | Vaccine | $14.2 | $21.7 | $10.0 | $35.0 | $50.0 | $130.9 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Botulinum | Next generation candidates | $0.0 | $0.0 | $0.0 | $25.0 | $25.0 | $50.0 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | BARDA EID | | $0.0 | $0.0 | $0.0 | $200.0 | $200.0 | $400.0 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | BARDA MCIP | Medical
Countermeasures Innovation | $7.0 | $39.0 | $55.0 | $150.0 | $150.0 | $401.0 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | BARDA Mgt & Admin | | $92.0 | $93.6 | $60.0 | $85.0 | $85.0 | $415.6 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Broad Spectrum Antimicrobials | BARDA CARB | $107.0 | $107.0 | $107.0 | $107.0 | $107.0 | $535.0 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Broad Spectrum Antimicrobials | | $109.3 | $33.0 | $73.0 | $123.0 | $123.0 | $461.3 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Chemical | | $50.5 | $35.7 | $60.0 | $115.0 | $115.0 | $376.2 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Chemical | Pharmaceutical-Based Agents | $0.0 | $0.0 | $0.0 | $350.0 | $0.0 | $350.0 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | CIADM | Operations | $0.0 | $0.0 | $0.0 | $75.0 | $50.0 | $125.0 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Cross-Cutting Science | Animal Models | $14.0 | $15.1 | $0.0 | $40.0 | $45.0 | $114.1 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Cross-Cutting Science | Clinical Services Network | $1.0 | $1.1 | $12.0 | $5.0 | $20.0 | $39.1 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Filoviruses | | $19.0 | $58.3 | $32.0 | $40.0 | $75.0 | $224.3 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Other Threats | Vaccine
Development | $0.0 | $0.0 | $0.0 | $75.0 | $0.0 | $75.0 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Rad/Nuc | ARS - Neutropenia/
Skin/Lung/GI | $75.2 | $66.4 | $60.0 | $100.0 | $120.0 | $421.6 |
|---|
| ASPR BARDA | Direct Appropriation, Multiyear | Rad/Nuc | Biodosimetry
and Biodiagnostics | $23.9 | $40.0 | $48.0 | $30.0 | $40.0 | $181.9 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Rad/Nuc | Thermal
Burn
Products | $13.4 | $28.7 | $30.0 | $50.0 | $50.0 | $172.1 |
|---|
ASPR
BARDA | Direct Appropriation, Multiyear | Smallpox | Vaccine/
Antivirals | $9.0 | $18.0 | $15.0 | $30.0 | $40.0 | $112.0 |
|---|
|
Subtotal (non-add) |
$1,514 |
$1,653 |
$1,698 |
$4,217 |
$3,671 |
$12,753 |
|---|
NIH | Direct
Appropriation,
Annual | Anthrax | Basic/Other
Research | $7.2 | $7.5 | $6.5 | $6.6 | $6.8 | $34.6 |
|---|
NIH | Direct
Appropriation,
Annual | Anthrax | Vaccines | $5.5 | $5.7 | $4.9 | $5.0 | $5.1 | $26.2 |
|---|
NIH | Direct
Appropriation,
Annual | Botulinum | Basic/Other
Research | $0.9 | $0.9 | $0.8 | $0.8 | $0.8 | $4.1 |
|---|
NIH | Direct
Appropriation,
Annual | Botulinum | Vaccines | $0.6 | $0.7 | $0.6 | $0.6 | $0.6 | $3.1 |
|---|
NIH | Direct
Appropriation,
Annual | Botulinum | Antitoxins | $2.8 | $2.9 | $2.5 | $2.6 | $2.7 | $13.5 |
|---|
NIH | Direct
Appropriation,
Annual | Broad
Spectrum
Antimicrobials | Antibiotics | $362.1 | $413.6 | $356.1 | $365.7 | $375.6 | $1,873.0 |
|---|
NIH | Direct
Appropriation,
Annual | Broad
Spectrum
Antimicrobials | Antivirals | $77.7 | $80.8 | $69.6 | $71.4 | $73.4 | $372.8 |
|---|
NIH | Direct
Appropriation,
Annual | Cross-Cutting
Science | Basic/Other
Research | $285.7 | $296.1 | $255.0 | $261.9 | $268.9 | $1,367.5 |
|---|
NIH | Direct
Appropriation,
Annual | Cross-Cutting
Science | Product
Development | $142.8 | $148.6 | $133.8 | $137.4 | $141.1 | $703.7 |
|---|
NIH | Direct
Appropriation,
Annual | Cross-Cutting
Science | Translational | $128.2 | $133.3 | $114.8 | $117.9 | $121.0 | $615.1 |
|---|
NIH | Direct
Appropriation,
Annual | Cross-Cutting
Science | Animal
Model | $22.2 | $23.1 | $19.9 | $20.4 | $21.0 | $106.5 |
|---|
NIH | Direct
Appropriation,
Annual | Filoviruses | Basic/Other
Research | $58.0 | $60.3 | $51.9 | $53.4 | $54.8 | $278.4 |
|---|
NIH | Direct
Appropriation,
Annual | Filoviruses | Vaccines | $44.8 | $46.6 | $40.1 | $41.2 | $42.3 | $214.9 |
|---|
NIH | Direct
Appropriation,
Annual | Pandemic
Influenza | Basic/Other
Research | $98.4 | $102.3 | $88.1 | $90.4 | $92.9 | $472.0 |
|---|
NIH | Direct
Appropriation,
Annual | Pandemic
Influenza | Vaccines | $149.7 | $195.7 | $168.5 | $173.0 | $177.7 | $864.7 |
|---|
NIH | Direct
Appropriation,
Annual | Multiplex
Diagnostics | Diagnostics | $101.9 | $106.0 | $91.3 | $93.7 | $96.3 | $489.1 |
|---|
NIH | Direct
Appropriation,
Annual | Other
Threats | Basic/Other
Research | $433.5 | $450.9 | $388.2 | $398.7 | $409.4 | $2,080.7 |
|---|
NIH | Direct
Appropriation,
Annual | Other
Threats | Vaccines | $104.8 | $109.0 | $93.9 | $96.4 | $99.0 | $503.1 |
|---|
NIH | Direct
Appropriation,
Annual | Smallpox | Basic/Other
Research | $10.2 | $10.6 | $9.1 | $9.4 | $9.6 | $48.9 |
|---|
NIH | Direct
Appropriation,
Annual | Smallpox | Vaccines | $1.0 | $1.0 | $0.9 | $0.9 | $0.9 | $4.6 |
|---|
NIH | Direct
Appropriation,
Annual | Plague/
Tularemia | Basic/Other
Research | $5.9 | $6.2 | $5.3 | $5.4 | $5.6 | $28.4 |
|---|
NIH | Direct
Appropriation,
Annual | Plague/
Tularemia | Vaccines | $2.7 | $2.8 | $2.4 | $2.5 | $2.5 | $12.9 |
|---|
NIH | Direct
Appropriation,
Annual | Broad
Spectrum
Antimicrobials | Antibiotics | $1.5 | $1.5 | $1.3 | $1.3 | $1.4 | $7.0 |
|---|
NIH | Direct
Appropriation,
Annual | Multiplex
Diagnostics | Diagnostics | $1.4 | $1.4 | $1.2 | $1.3 | $1.3 | $6.5 |
|---|
NIH | Direct
Appropriation,
Annual | Other Threats | Basic/Other
Research | $21.6 | $22.8 | $18.7 | $19.2 | $19.8 | $102.1 |
|---|
NIH | Direct
Appropriation,
Annual | Other Threats | Vaccines | $2.0 | $2.1 | $1.8 | $1.9 | $1.9 | $9.8 |
|---|
NIH | Direct
Appropriation,
Annual | Chemical | Chemical
Countermeasures
Research | $49.2 | $49.2 | $42.4 | $43.5 | $44.7 | $228.9 |
|---|
NIH | Direct
Appropriation,
Annual | Rad/Nuc | Nuclear/
Radiological
Countermeasures | $47.9 | $47.9 | $41.3 | $42.4 | $43.5 | $223.1 |
|---|
|
Subtotal (non-add) |
$2,170 |
$2,329 |
$2,011 |
$2,065 |
$2,121 |
$10,695 |
|---|
FDA | Direct
Appropriation,
Annual | FDA
Regulatory
Science | Antimicrobial
Resistance
MCM | $22.6 | $22.2 | $22.0 | $22.6 | $23.3 | $112.7 |
|---|
FDA | Direct
Appropriation,
Annual | FDA
Regulatory
Science | CBRN MCM
Base Funding
(pre-MCMi) | $48.4 | $48.6 | $57.2 | $58.9 | $60.7 | $273.8 |
|---|
FDA | Direct
Appropriation,
Annual | FDA
Regulatory
Science | MCMi
Annual | $24.6 | $24.6 | $31.6 | $46.1 | $47.5 | $174.3 |
|---|
FDA | Direct
Appropriation,
Annual | FDA
Regulatory
Science | Pandemic
Influenza
MCM | $40.5 | $41.1 | $43.7 | $45.0 | $46.3 | $216.6 |
|---|
FDA | Ebola
Emergency
Funding, Multiyear,
Direct | FDA
Regulatory
Science | Ebola
Emergency | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
|---|
FDA | Transfer from
No-Year
PI Funding | FDA
Regulatory
Science | Transfer from
No-Year
Pandemic
Influenza | $1.7 | $0.0 | $0.0 | $0.0 | $0.0 | $1.7 |
|---|
FDA | Direct
Appropriation,
Multiyear | FDA
Regulatory
Science | MCMi
Multiyear | $4.1 | $4.1 | $0.0 | $0.0 | $0.0 | $8.2 |
|---|
|
Subtotal (non-add) |
$142 |
$141 |
$154 |
$173 |
$178 |
$787 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Ancillary | Other
supportive
(incl. antimicrobials) | $17.0 | $0.0 | $10.9 | $36.5 | $27.6 | $92.1 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Ancillary | Therapeutic | $0.0 | $5.0 | $0.0 | $0.0 |
$0.0 | $5.0 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Anthrax | Antibiotic | $126.2 | $11.0 | $37.7 | $79.0 | $79.2 | $333.0 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Anthrax | Therapeutic | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Anthrax | Vaccine | $115.8 | $145.0 | $0.0 | $0.0 | $0.0 | $260.8 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Burkholderia | Antibiotic | $0.7 | $0.7 | $2.3 | $2.3 | $2.3 | $8.4 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Chemical | Anticonvulsant | $0.2 | $2.2 | $10.4 | $0.2 | $1.9 | $14.9 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Chemical | Nerve
agent antidote | $29.3 | $14.7 | $97.1 | $3.5 | $6.4 | $150.8 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | FMS | Antibiotic | $0.1 | $0.1 | $0.2 | $0.2 | $0.2 | $0.7 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Pandemic
Influenza | Antiviral | $47.5 | $25.5 | $9.0 | $222.7 | $222.7 | $527.3 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Rad/Nuc | Antibiotic | $0.0 | $0.0 | $0.0 | $0.3 | $0.0 | $0.3 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Rad/Nuc | Antiviral | $1.5 | $0.0 | $0.0 | $0.8 | $0.8 | $3.0 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Rad/Nuc | Decorporation | $6.4 | $0.0 | $3.2 | $3.2 | $3.2 | $16.1 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Rad/Nuc | Other
supportive
(incl. antimicrobials) | $2.1 | $5.0 | $4.1 | $7.1 | $7.4 | $25.6 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Smallpox | Antiviral | $1.6 | $1.6 | $1.1 | $0.8 | $1.1 | $6.2 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Smallpox | Uricosuric | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.1 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Smallpox | Vaccine | $78.4 | $136.4 | $143.7 | $248.2 | $263.4 | $870.1 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | SNS
Non-
Procurement | Operating | $15.0 | $28.1 | $28.9 | $29.8 | $30.7 | $132.5 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | SNS
Non-
Procurement | Sustainment | $91.0 | $148.9 | $122.5 | $126.2 | $130.0 | $618.6 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | SNS
Non-
Procurement | Program
Support | $77.6 | $85.5 | $87.8 | $90.5 | $93.2 | $434.6 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Smallpox | Vaccine | $0.0 | $0.0 | $0.0 | $0.0 | $196.0 | $196.0 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Chemical | Nerve
agent antidote | $0.0 | $0.0 | $0.0 | $22.4 | $19.2 | $41.6 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Rad/Nuc | Antineutropenic | $0.0 | $0.0 | $0.0 | $67.0 | $67.0 | $134.0 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Anthrax | Vaccine | $0.0 | $0.0 | $0.0 | $0.0 | $287.0 | $287.0 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Anthrax | Therapeutic | $0.0 | $0.0 | $0.0 | $136.0 | $17.9 | $153.9 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Rad/Nuc | Thermal
Burn Products | $0.0 | $0.0 | $4.0 | $4.0 | $4.0 | $12.0 |
|---|
ASPR
SNS | Direct
Appropriation,
No-Year | Smallpox | Antiviral | $0.0 | $0.0 | $57.1 | $0.0 | $196.0 | $253.1 |
|---|
|
Subtotal (non-add) |
$610 |
$610 |
$620 |
$1,081 |
$1,657 |
$4,578 |
|---|
